Sun Pharma Advanced Research Company (SPARC) is the top gainer on the BSE currently. The stock rose 7% to Rs.328.15 and it is now at Rs.320, up over 4%.

The company announced today morning that it got complete response letter from FDA for Xelpros. The CRL reference for recent FDA inspection at Sun Pharma Industries' Halol unit indicates satisfactory resolutions of deficiencies identified during inspection is needed for approval of Xelpro. This means it does not require any more additional data from the USFDA on CRL.

SPARC had out-licensed Xelpros to a subsidiary of Sun Pharma in June 2015.